Published : 26 Nov 2025
Aagami has been granted a contract extension by its US-based client, who is working on a Phase 3 EPO asset designed to aid in resuscitation following sudden cardiac arrest.
This emergency medicine has the potential to save numerous lives that might otherwise be lost.
Aagami supports the client by identifying EPO suppliers and pursuing licensing or co-development partnerships. These efforts will facilitate advancement into Phase 3 development and eventual commercialization.
Currently, there are no drugs available to reduce reperfusion injury during resuscitation from sudden cardiac arrest. Our client has developed a patented method for administering erythropoietin (EPO) during resuscitation after sudden cardiac arrest.
Key Highlights of the Asset:
· Represents the first treatment specifically targeting reperfusion injury during sudden cardiac arrest resuscitation.
· Commercialization does not require a large sales force.
· An IND application will soon be filed for a Phase 3 pivotal clinical trial, supporting opportunities for expedited drug development.
· There is an option to obtain orphan drug designation, offering additional market exclusivity in both the United States and Europe.
· After 351(a) approval, there is a potential pathway to the EPO biosimilar market, representing a US market share exceeding $1 billion.
· The approach is patented—“Facilitation of Resuscitation from Cardiac Arrest by Erythropoietin” (US 8,067,366 B2; EP 2349454 B1).
· The project features an experienced management team and scientific advisors focused on resuscitation research.
· There is a pipeline of new therapies and strategies for addressing life-threatening emergencies in both civilian and military settings, in pre-hospital and hospital environments.
Aagami has brought top level EPO suppliers as well as discussions for Licensing/Co-development. With the extension, we gain more room to capitalize on the ongoing discussions and forge definitive partnerships for our client.
With this contract extension, we are able to build on these efforts and establish key partnerships for our client.
For further information, please contact:
Godwyn Francis
Vice President
Email: action@aagami.com